1. Home
  2. PODD vs CG Comparison

PODD vs CG Comparison

Compare PODD & CG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$304.59

Market Cap

22.1B

Sector

Health Care

ML Signal

HOLD

Logo The Carlyle Group Inc.

CG

The Carlyle Group Inc.

HOLD

Current Price

$57.10

Market Cap

18.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PODD
CG
Founded
2000
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
22.1B
18.6B
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
PODD
CG
Price
$304.59
$57.10
Analyst Decision
Strong Buy
Buy
Analyst Count
19
16
Target Price
$359.00
$66.29
AVG Volume (30 Days)
765.6K
2.7M
Earning Date
11-06-2025
10-31-2025
Dividend Yield
N/A
2.45%
EPS Growth
N/A
445.01
EPS
3.45
1.78
Revenue
$2,521,800,000.00
$3,208,300,000.00
Revenue This Year
$32.55
N/A
Revenue Next Year
$20.39
$20.80
P/E Ratio
$88.24
$32.05
Revenue Growth
27.11
N/A
52 Week Low
$230.05
$33.02
52 Week High
$354.88
$69.85

Technical Indicators

Market Signals
Indicator
PODD
CG
Relative Strength Index (RSI) 40.94 61.74
Support Level $303.20 $53.25
Resistance Level $317.34 $54.78
Average True Range (ATR) 13.12 1.55
MACD -2.82 0.79
Stochastic Oscillator 3.14 93.17

Price Performance

Historical Comparison
PODD
CG

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About CG The Carlyle Group Inc.

Carlyle Group is one of the world's largest alternative-asset managers, with $474.1 billion in total AUM, including $332.0 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, which includes its private equity, real estate, infrastructure, and natural resources offerings (with $163.5 billion in total AUM and $101.1 billion in fee-earning AUM), global credit ($208.5 billion/$167.2 billion), and investment/fund solutions, known as Carlyle AlphInvest ($102.1 billion/$63.7 billion). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 3,100 active carry fund investors from 87 countries.

Share on Social Networks: